Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to $66.1 million.

  • Haemonetics' Net Cash Flow rose 13809.54% to $66.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $35.5 million, marking a year-over-year decrease of 7328.9%. This contributed to the annual value of $128.6 million for FY2025, which is 22553.35% up from last year.
  • Haemonetics' Net Cash Flow amounted to $66.1 million in Q4 2025, which was up 13809.54% from $4.3 million recorded in Q3 2025.
  • Over the past 5 years, Haemonetics' Net Cash Flow peaked at $167.1 million during Q2 2024, and registered a low of -$160.0 million during Q4 2023.
  • In the last 5 years, Haemonetics' Net Cash Flow had a median value of $4.8 million in 2021 and averaged $9.1 million.
  • Per our database at Business Quant, Haemonetics' Net Cash Flow plummeted by 63534.57% in 2023 and then soared by 507737.84% in 2024.
  • Over the past 5 years, Haemonetics' Net Cash Flow (Quarter) stood at $19.6 million in 2021, then crashed by 210.9% to -$21.8 million in 2022, then crashed by 635.35% to -$160.0 million in 2023, then skyrocketed by 117.35% to $27.8 million in 2024, then soared by 138.1% to $66.1 million in 2025.
  • Its last three reported values are $66.1 million in Q4 2025, $4.3 million for Q3 2025, and -$18.0 million during Q2 2025.